RNAtarget Technology by SOPHiA GENETICS
Maximize your insights from precious biopsy samples
Next-generation sequencing (NGS) has become the technology of choice for fusion detection in solid tumors. With a rapid increase in the number of fusion genes relevant in the clinical setting or management of solid tumors, running FISH or other single-gene methodologies can become resource intensive and unsustainable.
Meet RNAtarget Technology by SOPHiA GENETICS – a novel approach for robust fusion detection in small FFPE samples, enabling detection of SNV/Indels (in selected genes) and expression changes in as little as 10 ng of RNA. This technology adheres to the most up-to-date international guidelines recommending RNA-based novel fusion detection analysis to reduce the number of potential false negatives.
Customizable target region to detect variants perfectly fitting the needs of each lab
Optimized for small FFPE samples using 10ng RNA minimum input
Maximized fusion detection with high sensitivity
Detect SNV/Indels (in selected genes) and expression changes
Automation friendly streamlined 1.5-day workflow
Technology Details
Expect more from RNA analyses
The features of RNAtarget Technology align with the future of NGS testing in solid tumors:
Benefit from sensitive novel fusion detection
Fully guided design of amplicon-based solutions can limit the fusion genes detectable by the assay, potentially leading to false negative results. The capture-based design of RNAtarget Technology by SOPHiA GENETICS matches technical sensitivity of fully-guided amplicon-based solutions with 10ng of input while being able to detect more fusions due to novel fusion detection capability.
Highly performant fusion detection with minimal sample input
RNAtarget Technology can detect more fusions in minimal input material samples (20ng) compared to a standard amplicon-based solution with novel fusion detection capabilities.
Maximize insights from precious biopsy samples
RNAtarget Technology also detects SNVs/Indels in RNA to maximize insights from biopsy samples that are too small to be processed with a separate DNA workflow. SNV/Indel calling in RNA provides an indication of the expression and thus, of biological relevance of the detected mutation.
Contact us
Please fill out the form below to get in touch
Related products
SOPHiA DDM™ for Solid Tumors
From targeted to comprehensive genomic profiling, our solutions support healthcare professionals in their journey to analyze solid tumors.
